About climb bio inc - CLYM
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The firm develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
CLYM At a Glance
Climb Bio, Inc.
20 William Street
Wellesley Hills, Massachusetts 02481-4103
| Phone | 1-866-857-2596 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -59,851,000.00 | |
| Sector | Health Technology | Employees | 28 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CLYM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.191 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.518 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.003 |
CLYM Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,137,535.714 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CLYM Liquidity
| Current Ratio | 15.156 |
| Quick Ratio | 15.156 |
| Cash Ratio | 14.473 |
CLYM Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -31.097 |
| Return on Equity | -32.147 |
| Return on Total Capital | -37.171 |
| Return on Invested Capital | -32.09 |
CLYM Capital Structure
| Total Debt to Total Equity | 0.337 |
| Total Debt to Total Capital | 0.336 |
| Total Debt to Total Assets | 0.323 |
| Long-Term Debt to Equity | 0.178 |
| Long-Term Debt to Total Capital | 0.177 |